Please assess the completion status of the following clinical trial:

Trial Title: Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of PML confirmed by detection of JCV DNA in CSF.~* Onset of PML symptoms within 6 months prior to study.~Key Exclusion Criteria:~* Other opportunistic infection of the central nervous system.~* Current severe illness or any other conditions that, in the opinion of the Investigator, would make the subject unsuitable for enrollment.~* Active severe mental illness (e.g., depression, anxiety, psychosis, and schizophrenia).~* Hypersensitivity to mefloquine, quinine, or quinidine, or to any component of these drugs.~* Current treatment with quinine, quinidine, chloroquine, or halofantrine.~Note: Other protocol-defined criteria may also apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Local standard of care (Type: NO_INTERVENTION): All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.~Participants in this treatment arm had the option of adding 250 mg mefloquine by mouth at Week 4 (Day 28) or Week 8 (Day 56) daily for 3 days, and then weekly through Week 24.
- Local standard of care plus mefloquine 250 mg (Type: EXPERIMENTAL): All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.~Participants received 250 mg mefloquine by mouth on Days 0, 1, and 2 and then weekly through Week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).